Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$26.55 USD
-0.38 (-1.41%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $26.56 +0.01 (0.04%) 5:22 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Balance Sheet
Fiscal Year End for Myriad Genetics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 141 | 115 | 340 | 151 | 218 |
Receivables | 114 | 102 | 91 | 92 | 71 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 22 | 20 | 15 | 27 | 29 |
Other Current Assets | 36 | 38 | 38 | 120 | 14 |
Total Current Assets | 314 | 275 | 485 | 389 | 332 |
Net Property & Equipment | 119 | 83 | 44 | 41 | 37 |
Investments & Advances | 0 | 55 | 59 | 21 | 37 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 637 | 667 | 643 | 906 | 933 |
Deposits & Other Assets | 15 | 16 | 8 | 2 | 0 |
Total Assets | 1,147 | 1,199 | 1,321 | 1,419 | 1,405 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 26 | 29 | 30 | 21 | 22 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 114 | 94 | 157 | 79 | 76 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 5 | 33 | 36 |
Total Current Liabilities | 156 | 137 | 204 | 146 | 147 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 4 | 36 | 73 | 27 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 39 | 0 | 0 | 225 | 224 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 72 | 41 | 34 | 45 | 32 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 363 | 313 | 353 | 539 | 486 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,416 | 1,260 | 1,226 | 1,110 | 1,097 |
Retained Earnings | -630 | -366 | -254 | -233 | -174 |
Other Equity | -4 | -9 | -5 | 3 | -5 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 783 | 886 | 968 | 880 | 918 |
Total Liabilities & Shareholder's Equity | 1,147 | 1,199 | 1,321 | 1,419 | 1,405 |
Total Common Equity | 783 | 886 | 968 | 880 | 918 |
Shares Outstanding | 82.20 | 81.00 | 79.80 | 75.20 | 74.30 |
Book Value Per Share | 9.53 | 10.94 | 12.13 | 11.70 | 12.36 |
Fiscal Year End for Myriad Genetics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 97 | 104 | 141 | 86 | 122 |
Receivables | 118 | 118 | 114 | 115 | 112 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 26 | 25 | 22 | 25 | 23 |
Other Current Assets | 50 | 43 | 36 | 39 | 39 |
Total Current Assets | 292 | 290 | 314 | 265 | 294 |
Net Property & Equipment | 116 | 119 | 119 | 121 | 112 |
Investments & Advances | 0 | 0 | 0 | 0 | 6 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 606 | 628 | 637 | 643 | 646 |
Deposits & Other Assets | 15 | 15 | 15 | 16 | 22 |
Total Assets | 1,085 | 1,111 | 1,147 | 1,149 | 1,187 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 33 | 33 | 26 | 34 | 40 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 98 | 99 | 114 | 158 | 164 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 149 | 146 | 156 | 209 | 221 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 3 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 39 | 39 | 39 | 39 | 38 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 66 | 72 | 70 | 40 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 345 | 351 | 363 | 466 | 452 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,436 | 1,419 | 1,416 | 1,286 | 1,277 |
Retained Earnings | -692 | -656 | -630 | -598 | -537 |
Other Equity | -4 | -4 | -4 | -5 | -5 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 741 | 760 | 783 | 683 | 735 |
Total Liabilities & Shareholder's Equity | 1,085 | 1,111 | 1,147 | 1,149 | 1,187 |
Total Common Equity | 741 | 760 | 783 | 683 | 735 |
Shares Outstanding | 90.50 | 90.40 | 82.20 | 81.80 | 81.80 |
Book Value Per Share | 8.18 | 8.41 | 9.53 | 8.35 | 8.99 |